{"brief_title": "TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen", "brief_summary": "Primary objective: To determine the rate of confirmed treatment failure and relapse with an intermittent rifabutin-based regimen for the treatment of isoniazid and rifamycin-susceptible HIV-related tuberculosis (TB).", "condition": "Tuberculosis", "intervention_type": "Drug", "intervention_name": "Rifabutin", "criteria": "Inclusion Criteria - Clinical diagnosis of pulmonary &/or extrapulmonary TB confirmed by a positive culture and susceptibility to rifampin. Patients having isoniazid or pyrazinamide (PZA)-resistant isolates are eligible to continue in the study on a modified regimen - Evidence of HIV infection confirmed by a positive serologic test (ELISA and Western Blot). - Absolute neutrophil count >500/mm3 (use of colony stimulating factors, filgrastim, or sargramostim is allowed) - > 18 years of age - Willingness to practice effective contraception if applicable - Signed informed consent Exclusion Criteria - Pregnancy or breastfeeding - AST > 10 times the upper limit of normal - Bilirubin > 3.0 times the upper limit of normal - Creatinine > 3.0 times the upper limit of normal - Intolerance to any of the study drugs except isoniazid or pyrazinamide - Concomitant disorder that is contraindication to the use of the study drugs - More than 28 days of treatment for active tuberculosis within the 6 months prior to this course of therapy - Bone/joint tuberculosis or silicotuberculosis", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00023361.xml"}